Plasma p-tau217 Clocks for Predicting Onset of Symptomatic Alzheimer Disease
Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks
Clinical Question
Can plasma p-tau217 trajectories predict when a cognitively normal person will develop symptomatic Alzheimer disease?
Bottom Line
Longitudinal p-tau217 trajectories predict AD symptom onset years in advance. The rate of p-tau217 increase provides the most accurate prognostic information for preclinical AD.
Major Points
- Developed 'p-tau217 clocks' — trajectory models using serial blood measurements to predict time to symptomatic AD.
- Rate of p-tau217 change over time was a superior predictor vs single time-point measurement (P<0.05).
- Trajectory models significantly outperformed single measurements for predicting conversion (P<0.001).
- Prediction improved when combined with age, APOE genotype, and sex.
- Moves the field from diagnostic ('do you have AD?') to prognostic ('when will you get symptoms?') blood testing.
Design
Study Type: Longitudinal biomarker cohort study
Randomization:
Blinding: N/A
Follow-up Duration: Years of longitudinal follow-up
Centers: 0
Countries:
Sample Size: 0
Analysis: Trajectory modeling, time-to-event analysis
Inclusion Criteria
- Cognitively unimpaired at baseline
- Serial plasma p-tau217 measurements available
- Clinical follow-up for conversion to MCI/dementia
Arms
| Field | Longitudinal observational cohort |
|---|---|
| Intervention | Serial plasma p-tau217 measurements (no therapeutic intervention) |
| Duration | Years |
Outcomes
| Outcome | Type | Control | Intervention | HR / OR / RR | P-value |
|---|---|---|---|---|---|
| Rate of change vs absolute level | Secondary | Rate of change is better predictor | <0.05 | ||
| Combined with demographics | Secondary | Improved with age, APOE, sex | |||
| Observational biomarker study | Adverse | Prognostic biomarker study - no safety data extracted |
Criticisms
- Requires multiple blood draws over time — less practical than single time-point testing
- Prediction accuracy depends on number and spacing of serial measurements
- Ethical implications of predicting AD onset decades before symptoms are profound and unresolved
- Validated in research cohorts — performance in diverse clinical populations unknown
- Does not account for potential disease-modifying interventions that could alter trajectory
Based on: Plasma p-tau217 Clocks for Predicting Onset of Symptomatic Alzheimer Disease (Nature Medicine, 2026)
Citation: Nat Med. 2026.
Content summarized and formatted by NeuroTrials.ai.